Superparamagnetic nanoparticles as potential drug delivery systems for the treatment of Duchenne muscular dystrophy

被引:0
|
作者
Schumacher, Maria L. [1 ]
Britos, Tatiane N. [1 ]
Fonseca, Fernando L. A. [2 ]
Ferreira, Fabio F. [3 ,4 ]
Feder, David [2 ]
Fratini, Paula [2 ]
Petri, Giuliana [2 ]
Haddad, Paula S. [1 ]
机构
[1] Fed Univ Sao Paulo UNIFESP, Dept Chem, Diadema, SP, Brazil
[2] Fac Med ABC FMABC, Santo Andre, SP, Brazil
[3] Fed Univ ABC UFABC, Ctr Nat & Human Sci CCNH, Santo Andre, SP, Brazil
[4] Fed Univ ABC UFABC, Nanomed Res Unit NANOMED, Santo Andre, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
IRON-OXIDE NANOPARTICLES; CYSTEINE; MAGNETITE; HEMATITE; MRI;
D O I
10.1039/d4nr03407d
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
This study aims to use superparamagnetic iron oxide nanoparticles (SPIONs), specifically magnetite (Fe3O4), to deliver deflazacort (DFZ) and ibuprofen (IBU) to Duchenne muscular dystrophy-affected (DMD) mouse muscles using an external magnetic field. The SPIONs are synthesized by the co-precipitation method, and their surfaces are functionalized with l-cysteine to anchor the drugs, considering that the cysteine on the surface of the SPIONs in the solid state dimerizes to form the cystine molecule, creating the Fe3O4-(Cys)2-DFZ and Fe3O4-(Cys)2-IBU systems for in vivo tests. The Fe3O4 nanoparticles (NPs) were characterized by Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, powder X-ray diffraction (PXRD), transmission electron microscopy (TEM), dynamic light scattering (DLS), and magnetic measurements. The results show that the SPIONs have an average crystallite size of about 8 nm in the solid state and a hydrodynamic size of about 120 nm, which is suitable for biological applications in aqueous dispersion. The nanoparticles exhibit superparamagnetic behavior at room temperature and spherical-close morphology. In addition, vibrational modes characteristic of the functional groups of the molecules anchored to the surface of the SPIONs are identified. Data from blood tests of mdx mice after seven consecutive days of treatment with nanoparticles confirm the non-toxic nature of the system and show an improvement in DMD, with normal levels of liver and kidney enzymes and a decrease in creatine kinase protein.
引用
收藏
页码:3752 / 3767
页数:16
相关论文
共 50 条
  • [31] Drug development progress in duchenne muscular dystrophy
    Deng, Jiexin
    Zhang, Junshi
    Shi, Keli
    Liu, Zhigang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] RTCI4 demonstrates potential for treatment of Duchenne muscular dystrophy
    Bruce, Isaac
    FUTURE MEDICINAL CHEMISTRY, 2012, 4 (12) : 1534 - 1534
  • [33] Plumbagin: potential role in the co-treatment of Duchenne muscular dystrophy
    Prata, C.
    Pincigher, L.
    Zalambani, C.
    Barbalace, M. C.
    Zecchini, S.
    Ottria, R.
    De Palma, C.
    Malaguti, M.
    Clementi, E.
    Hrelia, S.
    Perrotta, C.
    FEBS OPEN BIO, 2024, 14 : 214 - 215
  • [34] Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy
    Consalvi, Silvia
    Saccone, Valentina
    Mozzetta, Chiara
    EPIGENOMICS, 2014, 6 (05) : 547 - 560
  • [35] Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy
    Himic, Vratko
    Davies, Kay E.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2021, 29 (09) : 1369 - 1376
  • [36] Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy
    Vratko Himič
    Kay E. Davies
    European Journal of Human Genetics, 2021, 29 : 1369 - 1376
  • [37] Compartmentalized vascular delivery of microdystrophin as a gene therapy treatment for Duchenne muscular dystrophy
    Rodino-Klapac, Louise R.
    Montgomery, Chrystal L.
    Clark, K. Reed
    Coley, Brian
    Jensen, Ryan
    Chicoine, Louis G.
    Mendell, Jery
    NEUROLOGY, 2007, 68 (12) : A1 - A2
  • [38] Reduced differentiation potential in Duchenne muscular dystrophy with increasing dystrophy
    Kottlors, M.
    Kirschner, J.
    NEUROMUSCULAR DISORDERS, 2007, 17 (9-10) : 841 - 841
  • [39] Hydroxyapatite nanoparticle mediated delivery of full length dystrophin gene as a potential therapeutic for the treatment of Duchenne muscular dystrophy
    Kotharkar, Pooja
    Talukdar, Indrani
    Ramanan, Sutapa Roy
    Ramesh, Keerthi
    Shastry, Arun
    Kowshik, Meenal
    NANOSCALE, 2025, 17 (04) : 2078 - 2090
  • [40] Targeted Delivery of Oligonucleotide Therapeutics to Muscle Demonstrates Potential to Treat Duchenne Muscular Dystrophy
    Subramanian, Romesh
    Yao, Monica
    Hsia, Nelson
    Qatanani, Mo
    Tang, Kim
    Shen, Christina
    Weeden, Tim
    MOLECULAR THERAPY, 2020, 28 (04) : 465 - 465